R. Nolan Townsend

R. Nolan Townsend is a seasoned executive currently serving as the Chief Executive Officer of Lexeo Therapeutics since January 2020. His appointment as CEO marked a new chapter after a substantial career at Pfizer, where he held various roles from 2008 to December 2019, culminating as President of Pfizer Rare Disease for the North America region.

Prior to his current role, he built a strong foundation in the pharmaceutical industry, demonstrating expertise in strategy, cross-functional leadership, and operational management. His work at Pfizer and subsequent leadership at Lexeo reflect his dedication to advancing biopharmaceutical innovations.

In addition to his executive responsibilities, he holds board positions at Arbor Biotechnologies and the Biotechnology Innovation Organization. His academic credentials, including a B.A. in Economics from the University of Pennsylvania and an M.B.A. from Harvard Business School, further complement his extensive professional experience.

Option Awards

• Grant Date: August 22, 2023
• Number of Shares: 106,472
• Exercise Price: $11.02 per share
• Grant Date Fair Value: $8.27 per share
• Grant Date Stock Price: $11.02 per share
• Vesting Schedule: 25% of the shares vest on August 22, 2024 with the remaining shares vesting in equal monthly installments over the following 36 months contingent on continuous service
• Performance Metrics & Targets: No specific performance metrics, targets, or thresholds provided

Non-Equity Incentive Plan Compensation

• Amount: $347,880
• Target Bonus: 55% of annual base salary ($575,000 as of October 1, 2023)
• Performance Metrics & Targets: No further performance criteria or detailed performance metrics provided